Company / Accounts Receivable
GYRE THERAPEUTICS, INC. Accounts Receivable History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$31.1M
FY2025
5-year range
$1.8M / $31.1M
FY2021-FY2025
Trend
+58.7%
vs FY2024
Sector context
#81 of 115
Health Care
What the data says
At $31M, GYRE THERAPEUTICS, INC.'s accounts receivable ranks #81 of 115 in the Health Care sector. Improved from $2M to $31M over the past 4 years.
Based on SEC 10-K filings.
$31M in FY2025 with a 5-year CAGR of +56.5%.
Improved from $2M to $31M over the past 4 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +56.5%
- 10-Year CAGR
- -
Sector benchmark
#81 of 115 in Health CareTop 70% of 115This company $31.1M Sector average $1.1B
▼
-97.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +56.5%, indicating consistent growth.
- In FY2025, accounts receivable increased 58.7% year-over-year.
- Ranks #81 out of 115 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.1M | +58.7% |
| FY2024 | $19.6M | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $1.8M | -45.1% |
| FY2020 | $3.3M | -77.9% |
| FY2019 | $15.0M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026